Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress The Financial Results and More  Today, July 31, 2025, Alnylam Pharmaceuticals (ALNY) - the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed recent business highlights. From Alnylam Pharmaceuticals Yvonne Greenstreet, M.D., Chief Executive Officer of . . . This content …

AstraZeneca Imfinzi Based on MATTERHORN Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free survival benefit If approved, this will be the first and only perioperative immunotherapy-based regimen in this setting AstraZeneca’s (AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review in the US for the treatment . . . This content is for …

Klotho Neurosciences to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity Indicators. On July 25, 2025,  Klotho Neurosciences, Inc. (KLTO) announced that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and also  longevity.  In addition to its core . . . This content is for paid subscribers. Please click here to subscribe …

GSK in the NEWS Today, GSK plc (GSK) announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). From GSK Court Horncastle, Senior Vice President at GSK, said,  “Too many people . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Eli Lilly Acquired Verve Therapeutics Eli Lilly and Company (LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (

AstraZeneca's Product Gefurulimab Once-weekly self-administered subcutaneous C5 inhibitor showed statistically significant and clinically meaningful reduction in disease severity at week 26.  Positive high-level results from a global, randomised, double-blind, placebo-controlled Phase III trial in adults with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalised myasthenia gravis showed that gefurulimab met its primary and all secondary endpoints. Data demonstrated a statistically significant and clinically meaningful improvement from baseline …

AstraZeneca in the NEWS Cornerstone of investment is a proposed new multi-billion dollar drug substance manufacturing center focused on chronic diseases in the Commonwealth of Virginia, the Company’s largest single Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% investment in a facility to date AstraZeneca (AZN) announces $50 billions of investment in the . . . This content is …

Axsome Therapeutics Axsome Therapeutics (AXSM) is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. The Company  delivers  scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Axsome industry-leading neuroscience portfolio includes FDA-approved . . . This content is for …

Friday, August 18, 2025 Solid Earning, revenue growth, President Trump signing crypto bills, and Crispr Therapeutics stocks finally surge with the stocks following are happening today in spite of  extreme bad weather in some states,  problems of important people from Epstein with many people visited him as friends not for anything else. While we enjoyed the surge of Crispr Therapeutics, we decided to remind the …

Q & A: Kiniksa Pharmaceuticals Q: Do you have any recent news from Kiniksa Pharmaceuticals?  A: Kiniksa Pharmaceuticals (KNSA) is a biopharmaceutical company that aims at  improving the lives of patients with debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need. The firm  focuses on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong . . . This …

The root-cause of the stock market’s volatility and inflation does not make sense as we are reading and hearing it. At the end of this week, we will post an article about this important subject, which will also explain the reason for the long pause of the Prohost Letter. Let’s have important news... Moderna to Report Q2 2025 Financial Results Moderna, Inc. (

Vertex Pharmaceuticals in the NEWS On Jul. 1, 2025, Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. From . . . This content is for paid subscribers. Please click here …